[1] McLENNAN S, FISHER E, MARTELL S Y. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells:possible role in diabetic nephropathy. 2000(zk). doi:10.1046/j.1523-1755.2000.07713.x
[2] MIGNATTI P. Extracellular matrix remodeling by metalloproteinases and plasminogen activators, 1995(zk)
[3] MURPHY G, KNAUPER V, COWELL S. Evaluation of some newer matrix metalloproteinases, 1999
[4] KUGLER A. Matrix metalloproteinasws and their inhibitors, 1999
[5] VU T H, WERB Z. Matrix metalloproteinases:effectors of development and normal physiology. 2000(17). doi:10.1101/gad.815400
[6] BODE W, FERNANDEZ-CATALAN C, GRAMS F. Insights into MMP-TIMP interactions, 1999
[7] WU K, SETTY S, MAUER S M. Altered kidney matrix gene expression in early stages of experimental diabetes, 1997
[8] EBIHARA L J, NAKAMURA T, SHIMADA N. Increased plasma metalloproteinase 9 concentrations precede development of microalbuminuria in non insulin dependent diabetes mellitus. 1998. doi:10.1016/S0272-6386(98)70035-6
[9] TASHIRO K, KOYANAGI I, OHARA I. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. 2004(3). doi:10.1002/jcla.20024
[10] GIUSEPPE D, MARIA A A, DIEGO G. Matrix Metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. 2004. doi:10.2337/diacare.27.1.273
[11] McLENNAN S V, KELLY D J, COX A J. Decreased matrix degradation in diabetic nephropathy:effects of ACE inhibition on the expression and activities of matrix metalloproteinases. 2002(2). doi:10.1007/s00125-001-0730-4
[12] SINGH R, SONG R H, ALAVI N. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta. 2001
[13] McLENNANS V, MARTELL S K Y, YUE D K. High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells:possible role in mesangium accumulation. 2000(5). doi:10.1007/s001250051353
[14] LUPIA E, ELLIOT S J, LENZ O. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells:implications for diabetic nephropathy. 1999(8). doi:10.2337/diabetes.48.8.1638
[15] McLENNAN S V, MARTELL S K Y, YUE D K. Effects of mesangium glycation on matrix metalloproteinase activities:possible role in diabetic nephropathy. 2002(8). doi:10.2337/diabetes.51.8.2612
[16] 于晓燕, 李才, 何泽. 糖基化终末产物对大鼠肾皮质基质金属蛋白酶2活性和表达的影响. 中华内分泌代谢杂志2003(5)
[17] BARICOS W H, CORTEZ S L, DEBOISBLANC M. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation cultured human mesangial cells, 1999
[18] McLENNAN S V, WANGX Y, MORENO V. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1:implications for diabetic nephropathy. 2004(12). doi:10.1210/en.2004-0436 |
